All News #Library
Biotech
Alys Pharma Doses First Subject in Ph 1/1b Chronic Urticaria
30 Oct 2025 //
PR NEWSWIRE
Alys Pharmaceuticals Submits CTA for ALY-301 in Cold Urticaria
10 Jun 2025 //
PR NEWSWIRE
Alys Pharma Receives IND Clearance for Phase 2a Dermatology Trial
04 Feb 2025 //
PR NEWSWIRE

Market Place
Sourcing Support